Advanced Search

 

Study ID Status Title Patient Level Data
49653/095 Completed A 26-week Randomised, Double-Blind, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Type 2 Diabetes who are Inadequately Controlled on Insulin Monotherapy Study Listed on ClinicalStudyDataRequest.com
49653/096 Completed A 26-week Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone when Administered Once Daily to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) who are Inadequately Controlled on… Study Listed on ClinicalStudyDataRequest.com
49653/097 Completed A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C 8mg once daily on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Study Listed on ClinicalStudyDataRequest.com
49653/098 Completed A Multicentre, Double-Blind, Parallel Group, Placebo-Controlled Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone When Administered Once Daily to Patients with Type 2 Diabetes Mellitus
49653/101 Completed A placebo controlled single-blind study on the safety, tolerance and pharmacokinetics of single and 8-day (u.i.d) repeat oral administration of BRL 49653C 8 mg in healthy adult volunteers
49653/105 Completed An Open-label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL 49653C When Administered as Monotherapy, Once Daily, to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/108 Completed A 16-Week Randomized, Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Hypolipidemic Therapy with an HMGCoA Reductase Inhibitor (Atorvastatin) in Type 2 Diabetes Mellitus Patients Treated with Rosiglitazone (BRL 49653C) 4mg bd
49653/109 Completed An Open-label, Positive-controlled, Parallel-group Study to Determine the Effect of BRL 49653C, Rosiglitazone, on Body Fat Distribution When Administered for 26 Weeks to Patients with Type 2 Diabetes Study Listed on ClinicalStudyDataRequest.com
49653/112 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Study Listed on ClinicalStudyDataRequest.com
49653/113 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of 49653 When Administered Once or Twice Daily in Combination with Metformin to Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/114 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone When Administered Once or Twice Daily in Combination with Insulin to Patients with Type 2 Diabetes Study Listed on ClinicalStudyDataRequest.com
49653/116 Completed An Investigation of the Effect of Rosiglitazone Maleate (BRL 49653C) Versus Troglitazone on the Safety, Tolerability and Pharmacokinetics of Triazolam in Healthy Volunteers
49653/117 Completed A Study to Evaluate the Relative Bioavailability of Two Enterically-Coated Formulations of Rosiglitazone Compared to the Immediate Release Formulation of Rosiglitazone in Healthy Volunteers.
49653/121 Completed An Investigation of the Pharmacokinetics of Single 4 mg and Repeat 4 mg Twice Daily and Single and Repeat 8 mg Once Daily Doses of Rosiglitazone in Healthy Volunteers
49653/125 Completed An Open-Label Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Type 2 Diabetes
49653/127 Completed A 26-Week Randomized, Double-Blind Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone 8mg/day (4mg bd) Versus Placebo in Combination with Glyburide in Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Maximum Dose Glyburide
49653/128 Completed A double-blind, multicenter, placebo controlled, parallel group comparative study to evaluate the efficacy and safety of BRL 49653C (Avandia) with concurrent sulphonylurea therapy, when administered to patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)
49653/129 Completed An Evaluation of the Safety and Tolerability of Single Rising Doses of Rosiglitazone in Healthy Chinese male Subjects.
49653/130 Completed An Evaluation of the Safety, Tolerability and Pharmacokinetics of Rosiglitazone after 8 Days Repeat –Dosing to Healthy Chinese Subjects.
49653/131 Completed A Double-blind, Placebo-controlled, Parallel-group Study to Determine the Effect of BRL- 49653C Rosiglitazone, on Fat Distribution When Administered for 26 Weeks to Subjects With Impaired Glucose Tolerance (IGT) Study Listed on ClinicalStudyDataRequest.com
49653/132 Completed A Multicentre, Double-Blind, Placebo Controlled, Parallel Group Comparative Study to Assess the Efficacy and Safety of Rosiglitazone with Concurrent Sulphonylurea Therapy when Administered to Subjects with Non-Insulin-Dependent Diabetes Mellitus (Type 2 Diabetes)
49653/133 Completed An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of Rosiglitazone (BRL 49653C) When Administered Twice Daily in Combination with Glyburide to Patients with Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Maximum Dose Glyburide (from study 49653-127)
49653/134 Completed A 26-Week Randomized, Double-Blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone (2 mg BID and 4 mg BID) Versus Placebo in Combination with Glyburide and Metformin in Patients with Type 2 Diabetes Mellitus
49653/135 Completed 2-year, Randomized, Double-blind, Parallel Group Study to Compare the Efficacy, Safety and Tolerability of Rosiglitazone Versus Placebo in Combination with Glipizide in Elderly Patients with Type 2 Diabetes Mellitus who are Inadequately Controlled on Glipizide Therapy Study Listed on ClinicalStudyDataRequest.com
49653/136 Completed A 26-week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rosiglitazone with Concurrent Insulin Therapy and/or a Sulphonylurea in Type 2 Diabetic Patients with Chronic Renal Failure (Not on Dialysis). Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.